Careers
Together, we can
accomplish more.
If you’re patient focused, passionate about what you do, and have an entrepenuerial spirit, you might be interested in learning more about working with us.
Explore Renibus’ career opportunities:

Join Our Team
Director/ Senior Director, Global Program Management
The Director/ Senior Director, Global Program Management at Renibus Therapeutics will play a critical role in overseeing programs from preclinical to Phase 3 and NDA filing. Together with program and functional leaders, this individual will drive the creation, development, implementation and tracking of global, integrated cross-functional project plans in alignment with their program strategies. This role will provide an independent perspective to the overall project strategy and drive decision making to ensure efficient program execution. In addition to timelines, they will be accountable for the tracking of program costs, as well as risk assessment and mitigation. This is an opportunity for a versatile individual to help establish the program management function as a key value driver for Renibus Therapeutics.

About Renibus Therapeutics
Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients’ lives by developing breakthrough products to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases. The Company has developed a robust portfolio of products that activate multiple cytoprotective pathways, including organ protection via preconditioning. Renibus’ first-in-class lead program, RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of Nrf2, IL-10, and ferritin. RBT-1 (stannic protoporfin/iron sucrose) is currently in Phase 2 development in cardiac surgery and will soon enter a Phase 3 registration study for its lead indication to reduce the risk of postoperative complications following cardiothoracic surgery. RBT-2 is an antioxidant and anti-fibrotic drug that has been shown to reduce the risk of CKD progression in preclinical models and will be in IND enabling and clinical development in 2023. RBT-3, a novel, low molecular weight iron nanoparticle, is one component of RBT-1 (stannic protoporfin/iron sucrose) and is targeted at reducing the risk of cisplatin-induced nephrotoxicity and will be taken into clinical development in 2023. RBT-9 (stannic protoporfin) is a potent anti-inflammatory and antioxidant drug with broad spectrum anti-viral properties. It has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19. Treatment with RBT-9 showed a statistically significant improvement in clinical status by 7 days (p<0.05) as well as a statistically significant reduction in hospital length of stay (-7.9 days, p<0.05). Additional pre-clinical work is underway to help inform the clinical development strategy.
Submit Your Resume
"*" indicates required fields